The art of developing innovative medical treatments can simply consist of reassigning how a compound is being used.
Just ask Dr. Evan Unger, who co-founded NuvOx Pharma, a Tucson-based research and development company.
Since 2008, NuvOx Pharma has focused on treating life-threatening diseases involving hypoxia, where oxygen is prevented from traveling to body tissue which disrupts metabolic functioning.
The company’s journey began when Unger licensed the rights to dodecafluoropentane emulsion, or DDFPe, which was originally developed for ultrasound technology. The company repurposed the compound for oxygen delivery therapies for patients who suffer from stroke, traumatic brain injury and hemorrhagic shock.
The company’s flagship program is for stroke treatment, Unger said, because of the size of the market. They believe the effectiveness of their therapy could make it the next standard of care. Approximately 795,000 Americans suffer from strokes each year.
Read the entire Tucson Local Media story here. Originally published April 24, 2019.